Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE-U Consortium

K. Beyer, R. Leenen, LDF. Venderbos, J. Helleman, F. Denijs, W. Bramer, V. Vasilyeva, E. Briers, JG. Rivas, R. Chloupkova, O. Majek, L. Annemans, P. Vynckier, P. Basu, A. Chandran, R. van den Bergh, S. Collen, H. van Poppel, MJ. Roobol, . On...

. 2024 ; 14 (1) : . [pub] 20240111

Status not-indexed Language English Country Switzerland

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc24006036

Grant support
001 World Health Organization - International

With the new policy recommendation in 2022 to explore the possibilities of screening for prostate cancer by the European Commission, the landscape for prostate cancer early detection is evolving. In line with this recommendation, the PRAISE-U project aims to evaluate the early detection and diagnosis of prostate cancer through customised and risk-based screening programmes, with the goal to align protocols across European Union member states. This systematic review is part of the PRAISE-U project, with the goal to review the policy, medical guideline recommendations, and the current level of opportunistic screening presented in the scientific literature on prostate cancer early detection from 2016 to 2023 in European Union member states. An extensive literature search was performed on 1 June 2023 in a large number of databases, including Embase.com, Medline (Ovid), Web of Science Core Collection, Google Scholar, and Policy Commons. We identified 318 articles (qualitative, quantitative, and reviews), of which 41 were included in the full-text screening. Seventeen articles were ultimately identified as eligible for inclusion. The included articles revealed significant variations towards PSA-based early detection policies for prostate cancer in nine European countries. Despite official recommendations, opportunistic screening was prevalent across all nine countries regardless of recommendations for or against PSA-based early detection. This systematic review suggests that the current early detection policies are not fit for purpose. High levels of opportunistic screening and overdiagnosis persist, prompting policy recommendations for standardised guidelines, informed decision making, and increased awareness to improve efficiency and effectiveness in early detection.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006036
003      
CZ-PrNML
005      
20240412130844.0
007      
ta
008      
240405s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jpm14010084 $2 doi
035    __
$a (PubMed)38248785
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Beyer, Katharina $u Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
245    10
$a Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE-U Consortium / $c K. Beyer, R. Leenen, LDF. Venderbos, J. Helleman, F. Denijs, W. Bramer, V. Vasilyeva, E. Briers, JG. Rivas, R. Chloupkova, O. Majek, L. Annemans, P. Vynckier, P. Basu, A. Chandran, R. van den Bergh, S. Collen, H. van Poppel, MJ. Roobol, . On Behalf Of The Praise-U Consortium
520    9_
$a With the new policy recommendation in 2022 to explore the possibilities of screening for prostate cancer by the European Commission, the landscape for prostate cancer early detection is evolving. In line with this recommendation, the PRAISE-U project aims to evaluate the early detection and diagnosis of prostate cancer through customised and risk-based screening programmes, with the goal to align protocols across European Union member states. This systematic review is part of the PRAISE-U project, with the goal to review the policy, medical guideline recommendations, and the current level of opportunistic screening presented in the scientific literature on prostate cancer early detection from 2016 to 2023 in European Union member states. An extensive literature search was performed on 1 June 2023 in a large number of databases, including Embase.com, Medline (Ovid), Web of Science Core Collection, Google Scholar, and Policy Commons. We identified 318 articles (qualitative, quantitative, and reviews), of which 41 were included in the full-text screening. Seventeen articles were ultimately identified as eligible for inclusion. The included articles revealed significant variations towards PSA-based early detection policies for prostate cancer in nine European countries. Despite official recommendations, opportunistic screening was prevalent across all nine countries regardless of recommendations for or against PSA-based early detection. This systematic review suggests that the current early detection policies are not fit for purpose. High levels of opportunistic screening and overdiagnosis persist, prompting policy recommendations for standardised guidelines, informed decision making, and increased awareness to improve efficiency and effectiveness in early detection.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Leenen, Renée $u Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
700    1_
$a Venderbos, Lionne D F $u Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands $1 https://orcid.org/0000000242690623
700    1_
$a Helleman, Jozien $u Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
700    1_
$a Denijs, Frederique $u Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
700    1_
$a Bramer, Wichor $u Medical Library, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
700    1_
$a Vasilyeva, Vera $u European Association of Urology, Policy Office, 6842 CV Arnhem, The Netherlands
700    1_
$a Briers, Erik $u Europa Uomo, 2018 Antwerp, Belgium
700    1_
$a Rivas, Juan Gomez $u Department of Urology, Clínico San Carlos University Hospital, 28040 Madrid, Spain $1 https://orcid.org/0000000205563035
700    1_
$a Chloupkova, Renata $u National Screening Centre, Institute of Health Information and Statistics of the Czech Republic, 128 01 Prague, Czech Republic $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $1 https://orcid.org/000000024091104X
700    1_
$a Majek, Ondrej $u National Screening Centre, Institute of Health Information and Statistics of the Czech Republic, 128 01 Prague, Czech Republic $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $1 https://orcid.org/0000000200343084
700    1_
$a Annemans, Lieven $u Department of Urology, Gasthuisberg University Hospital, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
700    1_
$a Vynckier, Pieter $u Department of Urology, Gasthuisberg University Hospital, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
700    1_
$a Basu, Partha $u International Agency for Research on Cancer, World Health Organization, 69366 Lyon, France
700    1_
$a Chandran, Arunah $u International Agency for Research on Cancer, World Health Organization, 69366 Lyon, France
700    1_
$a van den Bergh, Roderick $u Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
700    1_
$a Collen, Sarah $u European Association of Urology, Policy Office, 6842 CV Arnhem, The Netherlands
700    1_
$a van Poppel, Hendrik $u European Association of Urology, Policy Office, 6842 CV Arnhem, The Netherlands $1 https://orcid.org/0000000274588578
700    1_
$a Roobol, Monique J $u Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands $1 https://orcid.org/0000000169671708
700    1_
$a On Behalf Of The Praise-U Consortium,
773    0_
$w MED00203320 $t Journal of personalized medicine $x 2075-4426 $g Roč. 14, č. 1 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38248785 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240405 $b ABA008
991    __
$a 20240412130836 $b ABA008
999    __
$a ok $b bmc $g 2076101 $s 1215798
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 14 $c 1 $e 20240111 $i 2075-4426 $m Journal of personalized medicine $n J. pers. med. $x MED00203320
GRA    __
$a 001 $p World Health Organization $2 International
LZP    __
$a Pubmed-20240405

Find record

Citation metrics

Archiving options